Unlocking Hope: New Data from Open Label Extension of VILTEPSO® (viltolarsen) Injection to be Presented at MDA 2023 Conference

NS Pharma is delighted to take part in the 2023 Muscular Dystrophy Association’s Clinical & Scientific Congress in Dallas, Texas! We are proud to be part of this important event, which will bring together leading experts in the field of muscular dystrophy and related neuromuscular disorders to share their knowledge, experience, and research.

We look forward to engaging in meaningful discussions that will help advance our understanding of these conditions and ultimately improve the lives of those affected.

VILTEPSO® (viltolarsen) is set to present its long-term efficacy and safety data from an open-label extension of a Phase 2 study, with the final analysis extending up to Week 216. These results will provide further insight into the efficacy and safety of the drug over a prolonged period of time.

Dr. Edward Smith, a renowned physician from Duke University School of Medicine, will be delivering an enlightening and informative presentation. Don’t miss this opportunity to hear from one of the most esteemed members of the medical community!

Dr. Smith is proud to be a part of the Muscular Dystrophy Association’s Clinical & Scientific Congress this year, to help spread knowledge and awareness about the therapeutic treatments available to those living with Duchenne.

Thanks to the incredible advancements in science, patients and families can now benefit from a variety of treatments that provide long-term evidence of their effectiveness. The MDA is a key supporter of the Duchenne community, and Dr. Smith is honored to lend his expertise to the cause.

About VILTEPSO® (viltolarsen) injection

VILTEPSO, a revolutionary drug for the treatment of Duchenne Muscular Dystrophy (DMD), has been granted a number of designations in both the United States and Japan.

In the US, it was granted Priority Review, Rare Pediatric Disease, Orphan Drug and Fast Track Designations before its approval in August 2020. Similarly, in Japan, the drug was granted the SAKIGAKE designation, Orphan Drug designation, and designation of Conditional Early Approval System before it was approved for use in March 2020 for DMD patients amenable to exon 53 skipping therapy. This is a major breakthrough for DMD patients and their families.


VILTEPSO is a revolutionary treatment for Duchenne muscular dystrophy (DMD) that has been given approval under accelerated approval. It works by helping to increase dystrophin production in skeletal muscle, giving a much-needed boost to those suffering from DMD. While its effectiveness must still be confirmed in a confirmatory trial, VILTEPSO is a beacon of hope for those with DMD, offering a chance at a better quality of life.

Leave a Comment